Editorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes.
作者信息
Hollis Robert L, van Gent Mignon D J M
机构信息
The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
Department of Gynaecologic Oncology, Center for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam University Medical Centres, Amsterdam, Netherlands.
出版信息
Front Oncol. 2024 Dec 9;14:1519252. doi: 10.3389/fonc.2024.1519252. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes.社论：在深入了解和治疗罕见卵巢癌类型及亚型方面取得的进展
Front Oncol. 2024 Dec 9;14:1519252. doi: 10.3389/fonc.2024.1519252. eCollection 2024.
2
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.卵巢癌的形态学亚型：新进展和发病机制综述。
Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7.
3
The proteome of clear cell ovarian carcinoma.透明细胞卵巢癌的蛋白质组。
J Pathol. 2022 Dec;258(4):325-338. doi: 10.1002/path.6006. Epub 2022 Oct 14.
4
Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.与其他组织学类型的卵巢癌相比，卵巢癌肉瘤具有高度侵袭性。
Front Oncol. 2024 May 24;14:1399979. doi: 10.3389/fonc.2024.1399979. eCollection 2024.
5
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.早期低级别卵巢透明细胞癌与高级别组织学亚型相比：两个肿瘤中心的结局探索性分析。
Gynecol Oncol. 2021 Jan;160(1):64-70. doi: 10.1016/j.ygyno.2020.10.014. Epub 2020 Oct 17.
6
Rare ovarian tumors: an update on diagnosis and treatment.罕见卵巢肿瘤：诊断与治疗的最新进展。
Int J Gynecol Cancer. 2020 Jun;30(6):879-887. doi: 10.1136/ijgc-2020-001235. Epub 2020 May 26.
7
Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.恶性腹水在初诊时最常发生于高级别浆液性乳头状卵巢癌患者：2006 年至 2015 年在拜罗伊特医院治疗的 191 名女性的回顾性分析。
Arch Gynecol Obstet. 2019 Feb;299(2):515-523. doi: 10.1007/s00404-018-4952-9. Epub 2018 Nov 10.
8
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.激素受体表达与卵巢癌生存：卵巢肿瘤组织分析联盟研究。
Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.
9
The unique metabolome of clear cell ovarian carcinoma.透明细胞卵巢癌的独特代谢组。
J Pathol. 2024 Oct;264(2):160-173. doi: 10.1002/path.6329. Epub 2024 Aug 3.
10
Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.三种组织学类型（透明细胞型、子宫内膜样型和浆液性卵巢癌）中的基因表达谱。
J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):659-74.
本文引用的文献
1
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.整合基因组/表观基因组分析将透明细胞卵巢癌的亚型分层，突出了它们的细胞起源。
Sci Rep. 2024 Aug 13;14(1):18797. doi: 10.1038/s41598-024-69796-4.
2
The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.上皮性卵巢癌中完全肉眼切除与生存获益相关，具有组织学类型特异性。
JNCI Cancer Spectr. 2024 Jul 1;8(4). doi: 10.1093/jncics/pkae049.
3
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
4
Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.特定隔室的多组学分析确定 SRC 和 GNAS 为卵巢癌肉瘤上皮间质转化的候选驱动因素。
Br J Cancer. 2024 Feb;130(2):327-335. doi: 10.1038/s41416-023-02508-3. Epub 2023 Dec 14.
5
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.低级别浆液性卵巢癌的分子亚型与组织病理学特征及预后相关。
Sci Rep. 2023 May 11;13(1):7681. doi: 10.1038/s41598-023-34627-5.
6
Molecular characteristics and clinical behaviour of epithelial ovarian cancers.上皮性卵巢癌的分子特征和临床行为。
Cancer Lett. 2023 Feb 28;555:216057. doi: 10.1016/j.canlet.2023.216057. Epub 2023 Jan 7.
7
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.透明细胞卵巢癌的分子亚型及其对疾病行为和结局的影响。
Clin Cancer Res. 2022 Nov 14;28(22):4947-4956. doi: 10.1158/1078-0432.CCR-21-3817.
8
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.卵巢癌肉瘤是一种独特的卵巢癌形式，与输卵管-卵巢高级别浆液性癌相比，其生存率较差。
Br J Cancer. 2022 Oct;127(6):1034-1042. doi: 10.1038/s41416-022-01874-8. Epub 2022 Jun 17.
9
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.多组学特征分析高级别浆液性卵巢癌可实现高精度患者分层。
Clin Cancer Res. 2022 Aug 15;28(16):3546-3556. doi: 10.1158/1078-0432.CCR-22-0368.
10
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.曲美替尼对比标准治疗用于复发性低级别浆液性卵巢癌患者（GOG 281/LOGS）：一项国际性、随机、开放标签、多中心、2/3 期临床试验。
Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9.
Zotero 插件